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RNA INTERFERENCE AND ANTISENSE
APPROACH
There are basically two therapeutic oligonucleotides
antisense strategies to inhibit messenger RNA (mRNA). One
approach involves using DNA-based single-stranded oligo-
nucleotides referred to as antisense and the other using
an RNA-based double-stranded oligonucleotide (dsRNA)
known as interference (RNAi). Both entail Watson-Crick
binding. Both are oligonucleotides that target specific mRNA
for inhibition. Antisense DNA has been in clinical development
for some years now with a Food and Drug Administration-
approved product, fomivirsen (intraocular injection), as treat-
ment for CMV retinitis.1 RNAi is only now entering phase I
investigation. The existence of double-stranded RNA integral to
RNAi was found to exist in nature in 1998.2 RNAi has generated
considerable interest as a tool for studying gene function and as
a potential therapeutic strategy.3 In addition, it has far greater
potency than DNA-based antisense.4 Both strategies offer a
readier capacity to be designed against molecular targets com-
pared with small molecules given the ability, in principle, to
readily alter or create sequences to match any desired mRNA.
Summary of Presentations
There are multiple examples of successful targeted thera-
peutics, including trastuzumab, bevacizumab, etc. However,
these often fail to hit the intended molecular target given the
complexity of biochemistry. The easy definability of Watson-
Crick binding in the antisense DNA and RNA-based ap-
proaches, though not completely straightforward, may permit
more rapid development of agents that more reliably modu-
late the activity of the intended molecular targets.
Antisense: Antisense DNA are 13 to 25 single stranded
DNA molecules designed to hybridize to corresponding RNA to
inhibit protein translation. As a concept, it has been under
development for more than 30 years.1 On binding its mRNA
target by an incompletely understood process, the mRNA is
destroyed by endogenous enzymes such as RNase H or by
intrinsic enzymatic activity engineered into the antisense as
with ribozymes and DNAzymes.4 The antisense oligonucle-
otide is recovered to degrade additional mRNA. Antisense
molecules investigated in NSCLC in clinical trials include:
ISIS 3521 (PKC alpha) with no survival difference in two
phase III studies, OGX 011 (clusterin) studied in two phase II
studies in combination with platinum/gemcitabine (safe and
two partial responses) and paclitaxel (safe) with full results
pending, ISIS 2503 (H-ras) with 7/20 SD in a phase II, ISIS
5132 (raf-1) with fever in a phase I, Oblimersen (BclII) with
fever, LFTs increased in a phase I, and LY2181308 (surviv-
ing) under way in a phase I study.
RNAi: RNAi was discovered in 1998.2 It is antisense
using RNA oligonucleotides rather than DNA (convention-
ally, when using the word antisense, one is often referring to
antisense DNA oligonucleotides). Unlike antisense DNA,
RNAi requires a double-stranded RNA to make use of the
intracellular machinery to silence mRNA. This is known as
the RNA-induced silencing complex (RISC), which is har-
bored in the cytoplasm. The RISC machinery is triggered to
specifically silence a target mRNA when it binds short strands of
RNA that complement the mRNA. Silencing, the inhibition of
mRNA through RNAi, occurs through two mechanisms, mRNA
degradation when there is perfect homology and inhibition of
mRNA translation with imperfect homology. RNAi can be
triggered by a number of classes of engineered molecules,
including short interfering RNA (siRNA), short hairpin RNA
(shRNA), and bifunctional RNA.4
The siRNA is formed from a precursor that is chemi-
cally synthesized as a drug in the laboratory for exogenous
delivery to the cell. Once in the cytoplasm, it is processed by
a ribonuclease III-type enzyme called Dicer to form the
mature siRNA, which is 21-23 nt. RISC becomes activated
when one of the two strands from the siRNA is incorporated
into it. The siRNA guides the RISC complex to the target
mRNA in a sequence-specific fashion and induces endonu-
cleolytic cleavage when perfectly homologous. Once cleaved,
the entire mRNA molecule is rapidly degraded because of the
generation of unprotected RNA ends. The RISC complex is
recovered for further cleavage cycles.
Unlike siRNA, shRNAs is not chemically synthesized.
The structure and processing of shRNA is similar to mi-
croRNA (miRNA), a set of about 1000 endogenous inhibitors
of mRNA that are involved in normal physiology and also are
processed by RISC. miRNA was initially discovered in 1993,
well before the 1998 discovery that dsRNA is recognized by
cellular machinery.5 shRNA is modeled after miRNA and
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once matured, uses the same molecular machinery as siRNA.
Although miRNA is endogenous, shRNA precursors are
formed in the laboratory into a plasmid and can, in principle,
be designed (as a sequence) to target any gene. After delivery
to the cell nucleus, it is transcribed. The resultant primary
transcript (as with miRNA) is a stem loop also known as a
hairpin structure. The stem of the stem-loop structure is
formed from the self-complementary structure of the primary
transcript shRNA, which doubles back on itself and adheres
to its other end that has a reverse sequence of complementary
nucleotides. This transcript is further processed by the Drosha
enzyme complex in the nucleus, transported to the cytoplasm
and then is processed by Dicer (the same enzyme that
processes siRNA), which removes the loop forming a mature
double stranded shRNA. This is then incorporated into the
RISC structure. When nearly perfectly homologous, shRNA
results in total degradation of its target mRNA, whereas when
partially homologous, it inhibits translation. It is this last
mechanism of silencing that characterizes almost all miRNA
activity because miRNA is almost always only partially
homologous with its target mRNA, whereas shRNA is often
designed to be perfectly homologous.
siRNA is more rapid, less durable (hours) with less
easily regulated concentration compared with shRNA
(weeks), which, as a plasmid, can provide continuous syn-
thesis of shRNA precursors.4 Because shRNA is transcribed
in the nucleus, it is more subject to endogenous processing
and regulatory mechanisms that may explain why it is less off
target than siRNA. It may also yield fewer off target degra-
dation products than siRNA. shRNA also has the advantage
of the potential to regulate its expression through promoters.
In addition, shRNA can have a multiplex construction allow-
ing multiple mRNA targets with a single dose. However,
shRNA is slower because it needs to be transcribed before it
interacts with the RISC machinery. Bifunctional interference
entails use of a pair of shRNA with one member nearly
perfectly and the other imperfectly homologous to the target
mRNA. In this way, two different mechanisms of silencing,
degradation and inhibition of translation, will be elicited. This
has the potential benefit of more complete inhibition and
rapid onset compared with monofunctional shRNA given
effects on both mRNA turnover and protein kinetics while
still possessing the ability for more sustained inhibition.
Future Directions
Both DNA- and RNA-based antisense approaches have
been evaluated clinically. Clinical challenges to both strate-
gies include the difficulty they have crossing the cellular
membrane, given their size and negative charge and their lack
of stability in the serum. There are a large number of efforts
under way to further chemically modify the chemically syn-
thesized oligonucleotides. In addition, nanoparticle conjuga-
tions are in development to both improve stability in the
serum and uptake by targeted cells. On the other hand, there
is already a wealth of information both in the laboratory and
in the clinic on viral and liposomal vectors for gene delivery,
though here too, there is further development along many
lines in the laboratory. Future clinical study will integrate
changes in the biology and chemistry of the oligonucleotides
and associated nanoparticle carriers. Ultimately, cocktails of
oligonucleotide therapeutics can be envisioned to address the
multiplicity of genetic targets underlying cancer.
NANOPARTICLES
Nanoparticles (NP) are 3 to 200 nm systems that when
used for drug delivery can be made of a number of materials
including polymers such as polymeric NP, micelles, or den-
drimers; lipids (liposomes); viruses (viral NPs), and oragno-
metallic compounds such as nanotubes.6 They can facilitate
the disproportionate concentration of drugs to the cancer over
normal cells and can also be used to augment imaging of a
desired tissue.
Synopsis of Presentation
FUS1, a novel tumor suppressor gene, was found in the
3p21.3 gene cluster where allele losses from a number of
genes are frequent and occur early in many human cancers.7
It may be inactivated by haploinsufficiency. A loss of one of
the alleles is common. Loss of function of the second allele
does not seem to be typically caused by missense mutations
or C-terminal deletion mutations and there is no evidence of
promoter hypermethlyation. In addition, though FUS1 RNA
transcripts are detectable, endogenous FUS1 protein is not
detectable in most NSCLC and almost all small cell lung
cancer cell lines. Decrease in protein seems to be due to rapid
protein turnover from a defect in the protein’s myristoylation.7
This is because a myristoylation defective FUS1 protein has a
greatly reduced half-life.
Loss or reduction of FUS1 expression has be associated
with worse overall patient survival in NSCLC. FUS1 has
proapoptotic activity, inhibits multiple tyrosine kinases and
signaling, and there is evidence it increases IL-15 and NK
maturation as part of the inflammatory response. FUS 1
seems to mediate apoptosis in response to a stress. When
cytochrome c is released in response to a stress, FUS1 binds
APAF-1 thereby initiating APAF-1-mediated caspase activa-
tion and apoptosis. The proapoptotic effect may also occur
through its interaction with a number of tyrosine kinases and,
in doing so, also interfere with growth and other malignant
phenotypes. These tyrosine kinases include EGFR, PDGFR,
c-Abl, c-Kit, and AKT.
FUS1 has been complexed with a bilamellar invaginated
vesicle (BIV) or DOTAP-chol.8 Mixtures of these liposomal
NPs efficiently condense a variety of agents including nucleic
acids, proteins, viruses, and drugs. These complexes have a
number of promising properties including an extended half-life
in the circulation, broad biodistribution; they can target spe-
cific organs or cell types; are large enough to avoid Kupffer
cell clearance in the liver and yet can penetrate through tight
barriers in several organs; they fuse with cell membranes but
avoid endosomes; can be fractionated to produce totally
homogeneous populations of complexes by size before injec-
tion; and are nontoxic in animal studies, nonimmunogenic
and can be repeatedly administered.
In a clinical proof of principle experiment, expression
of luciferase in normal cells was far less than tumor cells
explanted from patients who had undergone surgery and had
had intravenous injection of DOTAP-chol complexed with
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luciferase containing plasmids. In a human NSCLC mouse
model, systemic injection of the FUS1-NP substantially inhib-
ited tumor growth, metastasis, and increased survival compared
with vehicle and myristoylated mutated FUS1 controls.
A phase I study of intravenous DOTAP:Chol-fus1 in
patients with advanced nonchemonaive NSCLC has been accru-
ing patients. The primary endpoints are toxicity and determina-
tion of the maximal tolerated dose. Secondary endpoints include
assessment of expression of FUS1 in tumor and normal bron-
chial epithelial cells and response and survival. Thus far, 23
patients have been accrued, 18 of whom are third line or more.
Four patients treated without premedications developed grade 2
or 3 fever. However, the 19 patients premedicated with dexa-
methasone and diphenhydramine did not develop a fever greater
than grade 1. No clinically significant drug-related toxicities
have been yet observed. Dose levels range from 0.01 to 0.09
mg/kg. Three patients achieved stable disease (4 months) and
15 of 23 patients received  2 doses. Median survival is
10.7 months. One patient had evidence of antitumor activ-
ity with decreased FDG activity on a repeat PET/CT.
Tumor samples from before and after treatment showed
uptake of FUS1 plasmid in two of three patients with a
normal control patient showing no FUS1.
Study of tyrosine kinases inhibited by FUS1 reveals po-
tential opportunities in personalized medicine and combination
therapy. Thus, evidence of elevated levels of c-abl in FUS1
deficient cell lines has implication for benefit from drugs such as
the bcr/abl inhibitor imatinib in some patients with NSCLC.9
The bcr/abl inhibitor, dasatinib, increased inhibition in combi-
nation with DOTAP:Chol-fus1 in an in vitro NSCLC model.
Reexpression of wt-FUS1 using FUS1-NP mediated gene
transfer into gefitinib and Erlotinib resistant FUS1 deficient
NSCLC cell lines with wt-EGFR sensitized them to gefitinib
with growth inhibition and increases in apoptosis and was
synergistic in vitro. Combination DOTAP:Chol-fus1 and ge-
fitinib was also synergistic in an orthotopic mouse model.
Next, Dr. Roth turned from a lipid based NP to a
theranostic (therapeutic  diagnostic) hybrid metallic NP
complexed with EGFR with potential use for both EGFR
specific imaging and enhanced anti-EGFR cancer therapy.10
The 50 to 70 nm NP is a hybrid that facilities both enhanced
optical and magnetic resonance imaging (MRI). It is formed
from a paramagnetic iron core (facilitating better MRI imag-
ing) coated with an outer gold layer that has special optical
properties for enhanced optical imaging. Anti-EGFR antibod-
ies are irreversibly conjugated to the gold. The gold is highly
effective at scattering light with the ability to engineer the
particle to reflect a desired wavelength of light which is
dependent on size, shape, and material and local environ-
ment. Because they are so bright but nanosized, the NPs can
be used as indicators of a single binding event. The Iron core
serves as a superparamagnet, which enhances the contrast
between the tissue of interest and the surrounding tissue
during an MRI by shortening the relaxation times of protons
within the target tissue. It is this alteration in the relaxation
time of the protons after aligning during an applied magnetic
field that enhances the differentiation of this tissue from
nontarget tissue on the MRI.
Phosphorlyated EGFR expressing NSCLC cell lines
were inhibited by the EGFR-targeted NPs compared with the
control NPs. Electron microscopy showed threefold dispro-
portionate uptake of EGFR targeted NPs into the cytoplasm
of EGFR positive cells compared with control NPs. Optical
imaging showed disproportionate uptake of labeled NPs in
the phospho-EGFR activated cell line, HCC82, but not in the
control cell line (H520). Cell kill in two phospho-EGFR acti-
vated cell lines was twice as high when using the EGFR-NP
compared with EGFR antibody alone and only a fifth the kill in
two different control NPs. In mouse experiments, EGFR-NPs
was administered on days 14, 15, and 16 and animal sacrifice
day 17 after HCC827 subcutaneous tumor injection. The
tumor tissue took up iron as indicated in stained specimens
and their growth was disproportionately inhibited compared
with the c-NP treated mice.
Future Directions
The field of NP facilitated targeted delivery and imag-
ing is developing along multiple lines in the laboratory and
clinic. NP can enhance the use of existing drugs and can
permit the use of novel classes of drugs, such as genes. Future
development of FUS1 gene therapy awaits the findings from
the ongoing phase I, but this trial demonstrates the feasibility
and tentative validation of the potential for systemic delivery
of therapeutic genes. The themes of personalized medicine,
facilitated in part by theranostics, and combination medicine,
both under rapid development, are illustrated here and will
play an ever greater role in the treatment of cancer.
MICELLAR NANOMEDICINE FOR LUNG
CANCER
Dr. Gao presented a talk titled, “Micellar Nanomedi-
cine for Lung Cancer.” The theme is personalized theranostic
nanomedicine. Theranostic (therapy diagnostic) nanomedi-
cine is defined by the speaker as an integrated nanotherapeu-
tic system which is able to diagnose and deliver a targeted
therapeutic and monitor the response.11 The four principles
underlying theranostic systems are targeting, controlled re-
lease, the therapeutic itself, and imaging.12 These can involve
a diversity of targeted moieties, drugs, a variety of nanopar-
ticles (liposomes, polymers, organometallic compounds, and
viruses), different control release systems, and a number of
imaging modalities. The theranostic principle is demon-
strated by the speaker using a system comprised of a
micelle encoding a peptide that targets lung cancers har-
boring the alphavbeta6 integrin. This enables targeting of
these lung cells with doxorubicin which is bonded to this
micelle in a controlled release system. The micelle also
contains a super paramagnetic iron oxide (SPIO) to en-
hance imaging of the target tissue using MRI.
Synopsis of Presentation
The major polymer-based nanotherapeutic systems are
polymer-drug conjugates, dendrimers, liposomes, and micelles.
Polymer-drug conjugates and liposomes have a longer history
and have had the most success in the clinic with the polymer-
drug, SMANCS, approved for liver cancer as an example and
Doxil an example of a liposomal-drug conjugate.12 Dendrim-
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ers show promise in in vivo models. A number of micelle
conjugates including those with doxorubicin and paclitaxel
are in phase I/II clinical trials. Unlike polymer-drug conju-
gates and dendrimer systems, drugs do not need to be co-
valently conjugated to micelles and liposomes freeing them
from specific chemical strategies (enzyme degradation, etc.)
to release the drug. However, there remains the option to
covalently bond a drug to the micelle. In addition, dendrimers
and polymer-drug conjugates have a much shorter blood
half-life given their small size and ease with which they cross
the glomeruli. Liposomes are vesicular self-assembled nano-
structures composed of phospholipid and cholesterol. Because
their inner compartment is hydrophilic, they are more suited to
water-soluble drugs such as proteins and DNAs. Polymeric
micelles are spherical self-assembling nanostructures. They have
a hydrophobic core, which serves as a reservoir for poorly
soluble lipophilic anticancer drugs, an attribute of most antican-
cer drugs. The outer shell of the micelle is hydrophilic, which
protects the micelle from rapid clearance.
Because micelles are small, there is limited drug loading
and faster release. By covalently conjugating drugs, such as
doxorubicin to the polymer constituents of the micelle, these
limitations can be decreased. Controlled release at the site of the
cellular target (as opposed to the blood stream) can occur
through a pH-sensitive covalent bond using a hydrazone linkage
from a PEG-pAsp copolymer of the micelle to doxorubicin.
Once the doxorubicin loaded micelle is in the low pH, endosome
it is released.13 Thus, the likelihood the doxorubicin released in
the cell rather than the serum is increased.
One way to target a micelle to the tissue of interest is to
label it with a peptide that specifically binds the target cell. In
the system described, a phage display peptide screen was
used to identify a peptide with a high probability of binding
NSCLC cells. The peptide, labeled LCP (III), bound the
largest percentage, 19 of 35 (54%) NSCLC cells lines among
those tested in vitro. The identified target of LCP (III), is
alphavbeta6 integrin.14 This integrin is overexpressed in many
lung cancer cells and its expression in tumors is correlated
with low survival. These two strategies, controlled release
and molecular targeting of the tumor, enable a higher dose of
doxorubicin to the cell. In an in vitro model, LCP (III)-encoded
micelles effectively targeted the alphavbeta6 integrin overex-
pressing NSCLC cell line, (H2009), but not the alphavbeta6,
integrin negative NSCLC cell line, (H460).
The diagnostics from this theranostic system derive
from loaded the micelle with SPIO. This has a higher sensi-
tivity than gadolinium-based contrast agents.15 SPIO loaded
micelles strongly perturb the local magnetic field resulting in
dramatic increase in T2 reflexivity of the protons in the
immediate environment thereby enhancing MRI imaging of
the target tissue. In a SCID mouse model, signal intensity
selectively dropped by more than a third in the alphavbeta6
integrin positive (H2009) subcutaneous NSCLC tumor but
not at all in the alphavbeta6 integrin negative (H460) tumor
within an 1 hour of injection of LCP (III) tagged SPIO loaded
micelles. This drop in intensity improves contrast against
higher intensity neighboring tissue. Next, the capacity to
target tumor and, in doing so, both image and treat it using the
theranostic principle was demonstrated using SPIO and doxo-
rubicin loaded micelles either tagged with LCP (III) or a
control peptide against a alphavbeta6 integrin positive NSCLC
line in a SCID mouse model. The LCP (III) tagging facilitated
a 2.6-fold increase in tumor targeting. Next, using the same
model, LCP (III) tagged micelles showed a dose response
against the alphavbeta6 integrin positive NSCLC tumors and
indeed, doxorubicin doses as high as 8 mg/kg were adminis-
tered weekly 5 doses, whereas free doxorubicin doses of 4
mg/kg killed the mice after a single injection. Thus, vastly
increased doses of doxorubicin and consequent efficacies
were achievable using this micelle system.
Future Directions
The theranostic principle was demonstrated in in vitro
and in vivo models by specifically targeting alphavbeta6
integrin positive tumors using micelles functionalized with
LCP(III). This enabled both enhanced imaging and treatment
of the target tumors. Further refinements in this system in the
laboratory are under way. Micelle-drug conjugates are al-
ready in clinical trials. Future trials will likely entail person-
alized micelle conjugates by integration of targeting moieties
thereby promising improved tolerability and efficacy.
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